Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease.

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders

Background:

• Pompe disease is a genetic disorder resulting in a deficiency of the enzyme acid alpha-glucosidase (GAA).
• This deficiency causes glycogen accumulation within lysosomes, particularly affecting skeletal muscle and leading to progressive muscle weakness.
• Current enzyme replacement therapy offers some benefit but does not fully address the disease's complex pathology.

Purpose of the Study:

• To investigate the role of metabolic abnormalities and energy deficits in Pompe disease pathogenesis.
• To evaluate the efficacy of a novel recombinant human GAA (AT-GAA) enzyme therapy in a pre-clinical model of Pompe disease.

Main Methods:

• Analysis of glycolytic pathway metabolites and energy source utilization in diseased muscle.
• Treatment of GAA-deficient mice with fully developed muscle pathology using AT-GAA.
• Assessment of disease pathogenesis markers and comparison with standard enzyme replacement therapy.

Main Results:

• Pompe disease muscle exhibits decreased glycolytic metabolites and a shift towards lipid utilization for energy.
• AT-GAA therapy significantly improved or reversed lysosomal glycogen entrapment, defective autophagy, and signaling pathway disruptions.
• The observed improvements with AT-GAA were superior to those achieved with the current standard of care therapy.

Conclusions:

• Metabolic dysfunction and energy deficits are key contributors to Pompe disease pathology.
• AT-GAA demonstrates superior efficacy in addressing multiple facets of Pompe disease pathogenesis compared to existing therapies.
• This novel enzyme replacement strategy holds promise for improving Pompe disease treatment outcomes.